Stempoint Capital
Latest statistics and disclosures from Stempoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, ABVX, PRAX, PRAX, SRZN, and represent 15.34% of Stempoint Capital's stock portfolio.
- Added to shares of these 10 stocks: ELVN (+$14M), CGON (+$14M), BHVN (+$14M), MBX (+$13M), PRAX (+$11M), CLDX (+$8.1M), SYRE (+$6.8M), MLYS (+$6.6M), DFTX (+$6.2M), BIOA (+$5.9M).
- Started 37 new stock positions in SPY, SLDB, BSX, XBI, FBRX, ERAS, EW, Helix Acquisition Corp Iii, STRO, ZURA.
- Reduced shares in these 10 stocks: CNTA (-$31M), TWST (-$23M), ACLX (-$22M), ROIV (-$16M), SRZN (-$12M), XENE (-$12M), MDGL (-$10M), ADPT (-$9.9M), PALI (-$9.9M), ABVX (-$8.7M).
- Sold out of its positions in ABBV, ADPT, APGE, ABUS, ACLX, ASND, BLTE, BBOT, DRUG, CNTA.
- Stempoint Capital was a net seller of stock by $-110M.
- Stempoint Capital has $792M in assets under management (AUM), dropping by 32.36%.
- Central Index Key (CIK): 0001952142
Tip: Access up to 7 years of quarterly data
Positions held by Stempoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stempoint Capital
Stempoint Capital holds 152 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 4.4 | $35M | -19% | 314k | 111.35 |
|
| Abivax Sa Sponsored Ads (ABVX) | 4.4 | $35M | -19% | 314k | 111.35 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.3 | $18M | +167% | 56k | 322.19 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.3 | $18M | +167% | 56k | 322.19 |
|
| Surrozen Com New (SRZN) | 1.9 | $15M | -68% | 526k | 29.13 |
|
| Mbx Biosciences (MBX) | 1.9 | $15M | +535% | 500k | 29.85 |
|
| Mbx Biosciences (MBX) | 1.9 | $15M | +535% | 500k | 29.85 |
|
| Mineralys Therapeutics (MLYS) | 1.8 | $14M | +83% | 533k | 27.09 |
|
| Mineralys Therapeutics (MLYS) | 1.8 | $14M | +83% | 533k | 27.09 |
|
| Enliven Therapeutics (ELVN) | 1.8 | $14M | NEW | 363k | 39.20 |
|
| Enliven Therapeutics (ELVN) | 1.8 | $14M | NEW | 363k | 39.20 |
|
| Cg Oncology (CGON) | 1.8 | $14M | NEW | 206k | 67.68 |
|
| Cg Oncology (CGON) | 1.8 | $14M | NEW | 206k | 67.68 |
|
| Biohaven (BHVN) | 1.7 | $14M | NEW | 1.6M | 8.46 |
|
| Biohaven (BHVN) | 1.7 | $14M | NEW | 1.6M | 8.46 |
|
| Roivant Sciences SHS (ROIV) | 1.3 | $11M | -60% | 386k | 27.70 |
|
| Roivant Sciences SHS (ROIV) | 1.3 | $11M | -60% | 386k | 27.70 |
|
| Eyepoint Com New (EYPT) | 1.3 | $11M | +129% | 811k | 12.89 |
|
| Eyepoint Com New (EYPT) | 1.3 | $11M | +129% | 811k | 12.89 |
|
| Arcutis Biotherapeutics (ARQT) | 1.2 | $9.7M | +84% | 414k | 23.56 |
|
| Arcutis Biotherapeutics (ARQT) | 1.2 | $9.7M | +84% | 414k | 23.56 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.2 | $9.7M | -42% | 200k | 48.20 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.2 | $9.7M | -42% | 200k | 48.20 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.2 | $9.3M | +18% | 670k | 13.90 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.2 | $9.3M | +18% | 670k | 13.90 |
|
| Dyne Therapeutics (DYN) | 1.2 | $9.2M | -39% | 506k | 18.13 |
|
| Dyne Therapeutics (DYN) | 1.2 | $9.2M | -39% | 506k | 18.13 |
|
| Edgewise Therapeutics (EWTX) | 1.2 | $9.2M | -19% | 291k | 31.50 |
|
| Edgewise Therapeutics (EWTX) | 1.2 | $9.2M | -19% | 291k | 31.50 |
|
| Cytokinetics Com New (CYTK) | 1.1 | $8.5M | -11% | 130k | 65.91 |
|
| Cytokinetics Com New (CYTK) | 1.1 | $8.5M | -11% | 130k | 65.91 |
|
| Spyre Therapeutics Com New (SYRE) | 1.1 | $8.5M | +417% | 168k | 50.44 |
|
| Spyre Therapeutics Com New (SYRE) | 1.1 | $8.5M | +417% | 168k | 50.44 |
|
| Denali Therapeutics (DNLI) | 1.0 | $8.2M | 427k | 19.20 |
|
|
| Denali Therapeutics (DNLI) | 1.0 | $8.2M | 427k | 19.20 |
|
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $8.2M | -59% | 141k | 58.15 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $8.2M | -59% | 141k | 58.15 |
|
| Celldex Therapeutics Com New (CLDX) | 1.0 | $8.1M | NEW | 254k | 31.72 |
|
| Celldex Therapeutics Com New (CLDX) | 1.0 | $8.1M | NEW | 254k | 31.72 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $7.6M | +22% | 73k | 105.40 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $7.6M | +22% | 73k | 105.40 |
|
| Dianthus Therapeutics (DNTH) | 0.9 | $7.2M | +7% | 86k | 83.92 |
|
| Dianthus Therapeutics (DNTH) | 0.9 | $7.2M | +7% | 86k | 83.92 |
|
| Celcuity (CELC) | 0.9 | $6.9M | -49% | 60k | 114.14 |
|
| Celcuity (CELC) | 0.9 | $6.9M | -49% | 60k | 114.14 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.8 | $6.2M | NEW | 326k | 18.90 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.8 | $6.2M | NEW | 326k | 18.90 |
|
| Scholar Rock Hldg Corp Call Option (SRRK) | 0.8 | $6.1M | -2% | 1.1M | 5.40 |
|
| Scholar Rock Hldg Corp Call Option (SRRK) | 0.8 | $6.1M | -2% | 1.1M | 5.40 |
|
| Bioage Labs (BIOA) | 0.7 | $5.9M | NEW | 339k | 17.49 |
|
| Bioage Labs (BIOA) | 0.7 | $5.9M | NEW | 339k | 17.49 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.7 | $5.8M | +147% | 181k | 32.01 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.7 | $5.8M | +147% | 181k | 32.01 |
|
| Surrozen Com New (SRZN) | 0.7 | $5.7M | -68% | 196k | 29.13 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $5.4M | NEW | 243k | 22.26 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $5.4M | NEW | 243k | 22.26 |
|
| Assembly Biosciences Com New (ASMB) | 0.7 | $5.1M | +18% | 185k | 27.75 |
|
| Assembly Biosciences Com New (ASMB) | 0.7 | $5.1M | +18% | 185k | 27.75 |
|
| Alumis (ALMS) | 0.6 | $5.1M | NEW | 230k | 22.03 |
|
| Alumis (ALMS) | 0.6 | $5.1M | NEW | 230k | 22.03 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $4.9M | NEW | 315k | 15.50 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $4.9M | NEW | 315k | 15.50 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.6 | $4.5M | NEW | 754k | 5.95 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.6 | $4.5M | NEW | 754k | 5.95 |
|
| Evommune Com Shs (EVMN) | 0.6 | $4.4M | +184% | 194k | 22.63 |
|
| Evommune Com Shs (EVMN) | 0.6 | $4.4M | +184% | 194k | 22.63 |
|
| Tango Therapeutics (TNGX) | 0.5 | $4.2M | NEW | 201k | 20.92 |
|
| Tango Therapeutics (TNGX) | 0.5 | $4.2M | NEW | 201k | 20.92 |
|
| Sensei Biotherapeutics Com New (SNSE) | 0.5 | $4.2M | NEW | 133k | 31.52 |
|
| Sensei Biotherapeutics Com New (SNSE) | 0.5 | $4.2M | NEW | 133k | 31.52 |
|
| Relmada Therapeutics (RLMD) | 0.5 | $4.2M | NEW | 597k | 6.96 |
|
| Relmada Therapeutics (RLMD) | 0.5 | $4.2M | NEW | 597k | 6.96 |
|
| Erasca (ERAS) | 0.5 | $3.9M | NEW | 240k | 16.18 |
|
| Erasca (ERAS) | 0.5 | $3.9M | NEW | 240k | 16.18 |
|
| Johnson & Johnson (JNJ) | 0.5 | $3.8M | -55% | 15k | 244.44 |
|
| Johnson & Johnson (JNJ) | 0.5 | $3.8M | -55% | 15k | 244.44 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $3.5M | -5% | 851k | 4.13 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.4 | $3.5M | -5% | 851k | 4.13 |
|
| Vaxcyte (PCVX) | 0.4 | $3.4M | NEW | 59k | 58.11 |
|
| Vaxcyte (PCVX) | 0.4 | $3.4M | NEW | 59k | 58.11 |
|
| Aadi Bioscience (WHWK) | 0.4 | $3.2M | -35% | 939k | 3.45 |
|
| Aadi Bioscience (WHWK) | 0.4 | $3.2M | -35% | 939k | 3.45 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs | 0.4 | $3.1M | NEW | 305k | 10.16 |
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs | 0.4 | $3.1M | NEW | 305k | 10.16 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $3.0M | NEW | 189k | 15.99 |
|
| Tenax Therapeutics Com New (TENX) | 0.4 | $3.0M | NEW | 189k | 15.99 |
|
| Alkermes SHS (ALKS) | 0.4 | $2.8M | NEW | 81k | 35.36 |
|
| Alkermes SHS (ALKS) | 0.4 | $2.8M | NEW | 81k | 35.36 |
|
| Pharvaris N V (PHVS) | 0.3 | $2.4M | +48% | 87k | 28.25 |
|
| Pharvaris N V (PHVS) | 0.3 | $2.4M | +48% | 87k | 28.25 |
|
| Adagio Therapeutics (IVVD) | 0.3 | $2.4M | +89% | 1.9M | 1.30 |
|
| Adagio Therapeutics (IVVD) | 0.3 | $2.4M | +89% | 1.9M | 1.30 |
|
| Jade Biosciences Com New (JBIO) | 0.3 | $2.2M | NEW | 154k | 14.05 |
|
| Jade Biosciences Com New (JBIO) | 0.3 | $2.2M | NEW | 154k | 14.05 |
|
| Immunovant Call Option (IMVT) | 0.3 | $2.2M | +31% | 847k | 2.55 |
|
| Immunovant Call Option (IMVT) | 0.3 | $2.2M | +31% | 847k | 2.55 |
|
| Twist Bioscience Corp (TWST) | 0.3 | $2.0M | -91% | 43k | 47.52 |
|
| Twist Bioscience Corp (TWST) | 0.3 | $2.0M | -91% | 43k | 47.52 |
|
| Maplight Therapeutics (MPLT) | 0.3 | $2.0M | 100k | 20.33 |
|
|
| Maplight Therapeutics (MPLT) | 0.3 | $2.0M | 100k | 20.33 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $2.0M | 135k | 14.93 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $2.0M | 135k | 14.93 |
|
|
| Revolution Medicines Put Option (RVMD) | 0.3 | $2.0M | +515% | 382k | 5.25 |
|
| Revolution Medicines Put Option (RVMD) | 0.3 | $2.0M | +515% | 382k | 5.25 |
|
| Ionis Pharmaceuticals (IONS) | 0.3 | $2.0M | NEW | 26k | 75.09 |
|
| Ionis Pharmaceuticals (IONS) | 0.3 | $2.0M | NEW | 26k | 75.09 |
|
| Immunocore Hldgs Ads (IMCR) | 0.2 | $1.9M | NEW | 64k | 30.15 |
|
| Immunocore Hldgs Ads (IMCR) | 0.2 | $1.9M | NEW | 64k | 30.15 |
|
| Forte Biosciences Com New (FBRX) | 0.2 | $1.5M | NEW | 58k | 25.90 |
|
| Forte Biosciences Com New (FBRX) | 0.2 | $1.5M | NEW | 58k | 25.90 |
|
| Sionna Therapeutics (SION) | 0.2 | $1.5M | NEW | 37k | 40.09 |
|
| Sionna Therapeutics (SION) | 0.2 | $1.5M | NEW | 37k | 40.09 |
|
| Sab Biotherapeutics Com New (SABS) | 0.2 | $1.4M | +155% | 375k | 3.83 |
|
| Sab Biotherapeutics Com New (SABS) | 0.2 | $1.4M | +155% | 375k | 3.83 |
|
| Solid Biosciences Com New (SLDB) | 0.2 | $1.4M | NEW | 195k | 7.20 |
|
| Solid Biosciences Com New (SLDB) | 0.2 | $1.4M | NEW | 195k | 7.20 |
|
| Lipocine Com New (LPCN) | 0.2 | $1.3M | NEW | 160k | 7.99 |
|
| Lipocine Com New (LPCN) | 0.2 | $1.3M | NEW | 160k | 7.99 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $1.3M | +79% | 78k | 16.35 |
|
| Uniqure Nv SHS (QURE) | 0.2 | $1.3M | +79% | 78k | 16.35 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.2 | $1.2M | NEW | 50k | 24.66 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.2 | $1.2M | NEW | 50k | 24.66 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.2 | $1.2M | NEW | 453k | 2.63 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.2 | $1.2M | NEW | 453k | 2.63 |
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $1.1M | +110% | 38k | 30.40 |
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $1.1M | +110% | 38k | 30.40 |
|
| Biodesix (BDSX) | 0.1 | $1.0M | NEW | 70k | 14.50 |
|
| Biodesix (BDSX) | 0.1 | $1.0M | NEW | 70k | 14.50 |
|
| Tyra Biosciences Call Option (TYRA) | 0.1 | $850k | NEW | 293k | 2.90 |
|
| Tyra Biosciences Call Option (TYRA) | 0.1 | $850k | NEW | 293k | 2.90 |
|
| Syndax Pharmaceuticals Call Option (SNDX) | 0.1 | $819k | 1.4M | 0.60 |
|
|
| Syndax Pharmaceuticals Call Option (SNDX) | 0.1 | $819k | 1.4M | 0.60 |
|
|
| Sutro Biopharma Com Shs (STRO) | 0.1 | $580k | NEW | 23k | 24.91 |
|
| Sutro Biopharma Com Shs (STRO) | 0.1 | $580k | NEW | 23k | 24.91 |
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $416k | NEW | 6.4k | 65.35 |
|
| Spruce Biosciences Com New (SPRB) | 0.1 | $416k | NEW | 6.4k | 65.35 |
|
| Spdr Series Trust State Street Spd Call Option (XBI) | 0.0 | $164k | NEW | 150k | 1.09 |
|
| Spdr Series Trust State Street Spd Call Option (XBI) | 0.0 | $164k | NEW | 150k | 1.09 |
|
| State Str Spdr S&p 500 Etf T Tr Unit Call Option (SPY) | 0.0 | $86k | NEW | 50k | 1.71 |
|
| State Str Spdr S&p 500 Etf T Tr Unit Call Option (SPY) | 0.0 | $86k | NEW | 50k | 1.71 |
|
| Invesco Qqq Tr Unit Ser 1 Call Option (QQQ) | 0.0 | $74k | NEW | 40k | 1.85 |
|
| Invesco Qqq Tr Unit Ser 1 Call Option (QQQ) | 0.0 | $74k | NEW | 40k | 1.85 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.0 | $58k | 617k | 0.09 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.0 | $58k | 617k | 0.09 |
|
|
| Boston Scientific Corporation Call Option (BSX) | 0.0 | $13k | NEW | 250k | 0.05 |
|
| Boston Scientific Corporation Call Option (BSX) | 0.0 | $13k | NEW | 250k | 0.05 |
|
| Terns Pharmaceuticals Call Option (TERN) | 0.0 | $7.5k | -76% | 100k | 0.07 |
|
| Terns Pharmaceuticals Call Option (TERN) | 0.0 | $7.5k | -76% | 100k | 0.07 |
|
| Olema Pharmaceuticals Call Option (OLMA) | 0.0 | $3.8k | NEW | 25k | 0.15 |
|
| Olema Pharmaceuticals Call Option (OLMA) | 0.0 | $3.8k | NEW | 25k | 0.15 |
|
| Edwards Lifesciences Call Option (EW) | 0.0 | $2.5k | NEW | 25k | 0.10 |
|
| Edwards Lifesciences Call Option (EW) | 0.0 | $2.5k | NEW | 25k | 0.10 |
|
Past Filings by Stempoint Capital
SEC 13F filings are viewable for Stempoint Capital going back to 2024
- Stempoint Capital 2026 Q1 amended filed May 18, 2026
- Stempoint Capital 2026 Q1 filed May 15, 2026
- Stempoint Capital 2025 Q4 filed Feb. 17, 2026
- Stempoint Capital 2025 Q3 filed Nov. 14, 2025
- Stempoint Capital 2025 Q2 filed Aug. 14, 2025
- Stempoint Capital 2025 Q1 filed May 15, 2025
- Stempoint Capital 2024 Q4 filed Feb. 14, 2025
- Stempoint Capital 2024 Q3 filed Nov. 13, 2024
- Stempoint Capital 2024 Q2 restated filed Aug. 13, 2024
- Stempoint Capital 2024 Q1 restated filed Aug. 9, 2024